{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:09:25Z","timestamp":1792069765112,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T00:00:00Z","timestamp":1644105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T00:00:00Z","timestamp":1644105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Oral Invest"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00784-022-04383-3","type":"journal-article","created":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T01:02:11Z","timestamp":1644109331000},"page":"2371-2382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Is serum C-terminal telopeptide cross-link of type 1 collagen a reliable parameter for predicting the risk of medication-related osteonecrosis of the jaws? A systematic review and meta-analysis of diagnostic test accuracy"],"prefix":"10.1007","volume":"26","author":[{"given":"Bassel","family":"Traboulsi-Garet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e0","family":"Jorba-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavi","family":"Camps-Font","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Abreu","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2122-6530","authenticated-orcid":false,"given":"Rui","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Valmaseda-Castell\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,6]]},"reference":[{"key":"4383_CR1","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","volume":"98","author":"RE Coleman","year":"2008","unstructured":"Coleman RE (2008) Risks and benefits of bisphosphonates. Br J Cancer 98:1736\u20131740. https:\/\/doi.org\/10.1038\/sj.bjc.6604382","journal-title":"Br J Cancer"},{"key":"4383_CR2","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J et al (2014) American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. J Oral Maxillofac Surg 72:1938\u20131956. https:\/\/doi.org\/10.1016\/j.joms.2014.04.031","journal-title":"J Oral Maxillofac Surg"},{"key":"4383_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/s0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115\u20131117. https:\/\/doi.org\/10.1016\/s0278-2391(03)00720-1","journal-title":"J Oral Maxillofac Surg"},{"key":"4383_CR4","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1200\/JCO.2003.99.132","volume":"21","author":"CA Migliorati","year":"2003","unstructured":"Migliorati CA (2003) Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253\u20134254. https:\/\/doi.org\/10.1200\/JCO.2003.99.132","journal-title":"J Clin Oncol"},{"key":"4383_CR5","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.joms.2009.02.004","volume":"67","author":"R Kunchur","year":"2009","unstructured":"Kunchur R, Need A, Hughes T, Goss A (2009) Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 67:1167\u20131173. https:\/\/doi.org\/10.1016\/j.joms.2009.02.004","journal-title":"J Oral Maxillofac Surg"},{"key":"4383_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/SCS.0000000000004224","volume":"29","author":"A Peisker","year":"2018","unstructured":"Peisker A, Raschke GF, Fahmy MD et al (2018) Cross-sectional study of four serological bone turnover markers for the risk assessment of medication-related osteonecrosis of the jaw. J Craniofac Surg 29:137\u2013140. https:\/\/doi.org\/10.1097\/SCS.0000000000004224","journal-title":"J Craniofac Surg"},{"key":"4383_CR7","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.joms.2015.09.028","volume":"74","author":"V Thumbigere-Math","year":"2016","unstructured":"Thumbigere-Math V, Michalowicz BS, Hughes PJ et al (2016) Serum markers of bone turnover and angiogenesis in patients with bisphosphonate-related osteonecrosis of the jaw after discontinuation of long-term intravenous bisphosphonate therapy. J Oral Maxillofac Surg 74:738\u2013746. https:\/\/doi.org\/10.1016\/j.joms.2015.09.028","journal-title":"J Oral Maxillofac Surg"},{"key":"4383_CR8","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.joms.2010.05.043","volume":"68","author":"TS Lazarovici","year":"2010","unstructured":"Lazarovici TS, Mesilaty-Gross S, Vered I et al (2010) Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg 68:2241\u20132247. https:\/\/doi.org\/10.1016\/j.joms.2010.05.043","journal-title":"J Oral Maxillofac Surg"},{"key":"4383_CR9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.oooo.2019.02.014","volume":"127","author":"V Moraschini","year":"2019","unstructured":"Moraschini V, de Almeida DCF, Figueredo CM, Calasans-Maia MD (2019) Association between biomarkers and medication-related osteonecrosis of the jaws: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol 127:504\u2013515. https:\/\/doi.org\/10.1016\/j.oooo.2019.02.014","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"4383_CR10","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","volume":"65","author":"RE Marx","year":"2007","unstructured":"Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397\u20132410. https:\/\/doi.org\/10.1016\/j.joms.2007.08.003","journal-title":"J Oral Maxillofac Surg"},{"key":"4383_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/cid.12297","volume":"18","author":"JW Kim","year":"2016","unstructured":"Kim JW, Cha IH, Kim SJ, Kim MR (2016) Biomarkers for bisphosphonate-related osteonecrosis of the jaw. Clin Implant Dent Relat Res 18:281\u2013291. https:\/\/doi.org\/10.1111\/cid.12297","journal-title":"Clin Implant Dent Relat Res"},{"key":"4383_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5624\/isd.2017.47.1.45","volume":"47","author":"HG Jeong","year":"2017","unstructured":"Jeong HG, Hwang JJ, Lee JH, Kim YH, Na JY, Han SS (2017) Risk factors of osteonecrosis of the jaw after tooth extraction in osteoporotic patients on oral bisphosphonates. Imaging Sci Dent 47:45\u201350. https:\/\/doi.org\/10.5624\/isd.2017.47.1.45","journal-title":"Imaging Sci Dent"},{"key":"4383_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.oooo.2017.07.011","volume":"124","author":"AAOM clinical practice statement","year":"2017","unstructured":"AAOM clinical practice statement (2017) Subject: The use of serum C-terminal telopeptide cross-link of type 1 collagen (CTX) testing in predicting risk of osteonecrosis of the jaw (ONJ). Oral Surg Oral Med Oral Pathol Oral Radiol 124:367\u2013368. https:\/\/doi.org\/10.1016\/j.oooo.2017.07.011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"4383_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.adaj.2016.02.011","volume":"147","author":"R Enciso","year":"2016","unstructured":"Enciso R, Keaton J, Saleh N, Ahmadieh A, Clark GT, Sedghizadeh PP (2016) Assessing the utility of serum C-telopeptide cross-link of type 1 collagen as a predictor of bisphosphonate-related osteonecrosis of the jaw: a systematic review and meta-analysis. J Am Dent Assoc 147:551\u2013560. https:\/\/doi.org\/10.1016\/j.adaj.2016.02.011","journal-title":"J Am Dent Assoc"},{"key":"4383_CR15","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.adaj.2019.03.006","volume":"150","author":"ME Awad","year":"2019","unstructured":"Awad ME, Sun C, Jernigan J, Elsalanty M (2019) Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: systematic review and meta-analysis. J Am Dent Assoc 150:664\u2013675. https:\/\/doi.org\/10.1016\/j.adaj.2019.03.006","journal-title":"J Am Dent Assoc"},{"key":"4383_CR16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1001\/jama.2017.19163","volume":"319","author":"MDF McInnes","year":"2018","unstructured":"McInnes MDF, Moher D, Thombs BD et al (2018) Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: The PRISMA-DTA statement. JAMA 319:388\u2013396","journal-title":"JAMA"},{"key":"4383_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529\u2013536. https:\/\/doi.org\/10.7326\/0003-4819-155-8-201110180-00009","journal-title":"Ann Intern Med"},{"key":"4383_CR18","doi-asserted-by":"publisher","unstructured":"Sch\u00fcnemann HJ, Cuello C, Akl EA et al (2019) Grade guidelines: 18. How robins-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol 111:105\u201314.\u00a0https:\/\/doi.org\/10.1016\/j.jclinepi.2018.01.012","DOI":"10.1016\/j.jclinepi.2018.01.012"},{"key":"4383_CR19","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.joms.2014.02.036","volume":"72","author":"A Hutcheson","year":"2014","unstructured":"Hutcheson A, Cheng A, Kunchar R, Stein B, Sambrook P, Goss A (2014) A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study. J Oral Maxillofac Surg 72:1456\u20131462. https:\/\/doi.org\/10.1016\/j.joms.2014.02.036","journal-title":"J Oral Maxillofac Surg"},{"key":"4383_CR20","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jcms.2017.05.003","volume":"45","author":"G Topaloglu","year":"2017","unstructured":"Topaloglu G, Koseoglu OT, Karaca C, Kosemehmetoglu K (2017) The effect of chronic dental inflammation on development of Stage 0 medication-related osteonecrosis of the jaw. J Cranio-Maxillofacial Surg 45:1158\u20131164. https:\/\/doi.org\/10.1016\/j.jcms.2017.05.003","journal-title":"J Cranio-Maxillofacial Surg"},{"key":"4383_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s13167-019-0160-3","volume":"10","author":"M Salgueiro","year":"2019","unstructured":"Salgueiro M, Stribos M, Zhang LF, Stevens M, Awad ME, Elsalanty M (2019) Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study. EPMA J 10:21\u201329. https:\/\/doi.org\/10.1007\/s13167-019-0160-3","journal-title":"EPMA J"},{"key":"4383_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.bone.2018.04.020","volume":"116","author":"DW Kim","year":"2018","unstructured":"Kim DW, Kim H, Nam W, Kim HJ, Cha I-H (2018) Machine learning to predict the occurrence of bisphosphonate-related osteonecrosis of the jaw associated with dental extraction: a preliminary report. Bone 116:207\u2013214. https:\/\/doi.org\/10.1016\/j.bone.2018.04.020","journal-title":"Bone"},{"key":"4383_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3\u201323. https:\/\/doi.org\/10.1002\/jbmr.2405","journal-title":"J Bone Miner Res"},{"key":"4383_CR24","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1007\/s00784-014-1205-6","volume":"18","author":"C Walter","year":"2014","unstructured":"Walter C, Sagheb K, Bitzer J, Rahimi-Nedjat R, Taylor KJ (2014) Analysis of reasons for osteonecrosis of the jaws. Clin Oral Investig 18:2221\u20132226. https:\/\/doi.org\/10.1007\/s00784-014-1205-6","journal-title":"Clin Oral Investig"},{"key":"4383_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jcms.2011.10.024","volume":"40","author":"Y A\u00e7il","year":"2012","unstructured":"A\u00e7il Y, M\u00f6ller B, Niehoff P et al (2012) The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells. J Cranio-Maxillofacial Surg 40:229\u2013235. https:\/\/doi.org\/10.1016\/j.jcms.2011.10.024","journal-title":"J Cranio-Maxillofacial Surg"},{"key":"4383_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00784-009-0365-2","volume":"15","author":"T Ziebart","year":"2011","unstructured":"Ziebart T, Pabst A, Klein MO et al (2011) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: Inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig 15:105\u2013111. https:\/\/doi.org\/10.1007\/s00784-009-0365-2","journal-title":"Clin Oral Investig"},{"key":"4383_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1359\/jbmr.091009","volume":"25","author":"AJ Roelofs","year":"2010","unstructured":"Roelofs AJ, Coxon FP, Ebetino FH et al (2010) Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 25:606\u2013616. https:\/\/doi.org\/10.1359\/jbmr.091009","journal-title":"J Bone Miner Res"},{"key":"4383_CR28","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.joms.2008.01.026","volume":"66","author":"R Landesberg","year":"2008","unstructured":"Landesberg R, Cozin M, Cremers S et al (2008) Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66:839\u2013847. https:\/\/doi.org\/10.1016\/j.joms.2008.01.026","journal-title":"J Oral Maxillofac Surg"},{"key":"4383_CR29","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s00198-017-4063-7","volume":"28","author":"T Hasegawa","year":"2017","unstructured":"Hasegawa T, Kawakita A, Ueda N et al (2017) (2017) A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ? Osteoporos Int 28:2465\u20132473. https:\/\/doi.org\/10.1007\/s00198-017-4063-7","journal-title":"Osteoporos Int"},{"key":"4383_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.joms.2009.01.011","volume":"67","author":"JE Fantasia","year":"2009","unstructured":"Fantasia JE (2009) Bisphosphonates-what the dentist needs to know: practical considerations. J Oral Maxillofac Surg 67:53\u201360. https:\/\/doi.org\/10.1016\/j.joms.2009.01.011","journal-title":"J Oral Maxillofac Surg"},{"key":"4383_CR31","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.ijom.2016.04.010","volume":"45","author":"SE N\u00f8rholt","year":"2016","unstructured":"N\u00f8rholt SE, Hartlev J (2016) Surgical treatment of osteonecrosis of the jaw with the use of platelet-rich fibrin: a prospective study of 15 patients. Int J Oral Maxillofac Surg 45:1256\u20131260. https:\/\/doi.org\/10.1016\/j.ijom.2016.04.010","journal-title":"Int J Oral Maxillofac Surg"},{"key":"4383_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00784-016-1762-y","volume":"21","author":"A Matsumoto","year":"2017","unstructured":"Matsumoto A, Sasaki M, Schmelzeisen R, Oyama Y, Mori Y, Voss PJ (2017) Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab. Clin Oral Investig 21:127\u2013134. https:\/\/doi.org\/10.1007\/s00784-016-1762-y","journal-title":"Clin Oral Investig"},{"key":"4383_CR33","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/jcpe.12455","volume":"42","author":"E Gaudin","year":"2015","unstructured":"Gaudin E, Seidel L, Bacevic M, Rompen E, Lambert F (2015) Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis. J Clin Periodontol 42:922\u2013932. https:\/\/doi.org\/10.1111\/jcpe.12455","journal-title":"J Clin Periodontol"},{"key":"4383_CR34","doi-asserted-by":"publisher","first-page":"CD012432","DOI":"10.1002\/14651858.CD012432.pub2","volume":"10","author":"Mayer BN Beth-tasdogan","year":"2017","unstructured":"Beth-tasdogan Mayer BN, Hussein H, Zolk O (2017) Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev 10:CD012432. https:\/\/doi.org\/10.1002\/14651858.CD012432.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4383_CR35","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/jbmr.1769","volume":"28","author":"S Kalyan","year":"2013","unstructured":"Kalyan S, Quabius ES, Wiltfang J, Monig H, Kabelitz D (2013) Can peripheral blood gd T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug effects of amino- bisphosphonate therapy. J Bone Miner Res 28:728\u2013735. https:\/\/doi.org\/10.1002\/jbmr.1769","journal-title":"J Bone Miner Res"},{"key":"4383_CR36","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/jbmr.37","volume":"25","author":"T Kikuiri","year":"2010","unstructured":"Kikuiri T, Kim I, Yamaza T et al (2010) Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res 25:1668\u20131679. https:\/\/doi.org\/10.1002\/jbmr.37","journal-title":"J Bone Miner Res"},{"key":"4383_CR37","doi-asserted-by":"publisher","first-page":"542","DOI":"10.4317\/medoral.22128","volume":"22","author":"L Bagan","year":"2017","unstructured":"Bagan L, Jim\u00e9nez Y, Leopoldo M, Rubert A, Bagan J (2017) Serum levels of RANKL and OPG, and the RANKL\/OPG ratio in bisphosphonate-related osteonecrosis of the jaw: are they useful biomarkers for the advanced stages of osteonecrosis? Med Oral Patol Oral Cir Bucal 22:542\u2013547. https:\/\/doi.org\/10.4317\/medoral.22128","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"4383_CR38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.bone.2013.08.005","volume":"57","author":"JW Kim","year":"2013","unstructured":"Kim JW, Kong KA, Kim SJ, Choi SK, Cha IH, Kim MR (2013) Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates. Bone 57:201\u2013205. https:\/\/doi.org\/10.1016\/j.bone.2013.08.005","journal-title":"Bone"},{"key":"4383_CR39","doi-asserted-by":"publisher","first-page":"CD008587","DOI":"10.1002\/14651858.CD008587.pub2","volume":"8","author":"G Koliopoulos","year":"2017","unstructured":"Koliopoulos G, Vn N, Santesso N et al (2017) Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev 8:CD008587. https:\/\/doi.org\/10.1002\/14651858.CD008587.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4383_CR40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2490-9-14","volume":"9","author":"P Harvey","year":"2009","unstructured":"Harvey P, Basuita A, Endersby D, Curtis B, Iacovidou A, Walker M (2009) A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol 9:14. https:\/\/doi.org\/10.1186\/1471-2490-9-14","journal-title":"BMC Urol"},{"key":"4383_CR41","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.joen.2018.01.021","volume":"44","author":"A Mainkar","year":"2018","unstructured":"Mainkar A, Kim SG (2018) Diagnostic accuracy of 5 dental pulp tests: a systematic review and meta-analysis. J Endod 44:694\u2013702. https:\/\/doi.org\/10.1016\/j.joen.2018.01.021","journal-title":"J Endod"},{"key":"4383_CR42","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","volume":"142","author":"JW Hellstein","year":"2011","unstructured":"Hellstein JW, Adler RA, Edwards B et al (2011) Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 142:1243\u20131251. https:\/\/doi.org\/10.14219\/jada.archive.2011.0108","journal-title":"J Am Dent Assoc"},{"key":"4383_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/ID.0b013e3181cec8bc","volume":"19","author":"CY Lee","year":"2010","unstructured":"Lee CY, Suzuki JB (2010) CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study. Implant Dent 19:29\u201338. https:\/\/doi.org\/10.1097\/ID.0b013e3181cec8bc","journal-title":"Implant Dent"},{"key":"4383_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11914-011-0091-y","volume":"10","author":"JT Schousboe","year":"2012","unstructured":"Schousboe JT, Bauer DC (2012) Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy. Curr Osteoporos Rep 10:56\u201363. https:\/\/doi.org\/10.1007\/s11914-011-0091-y","journal-title":"Curr Osteoporos Rep"}],"container-title":["Clinical Oral Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-022-04383-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00784-022-04383-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-022-04383-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T05:31:47Z","timestamp":1646458307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00784-022-04383-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,6]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["4383"],"URL":"https:\/\/doi.org\/10.1007\/s00784-022-04383-3","relation":{},"ISSN":["1432-6981","1436-3771"],"issn-type":[{"value":"1432-6981","type":"print"},{"value":"1436-3771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,6]]},"assertion":[{"value":"22 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not report on any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Dr. Octavi Camps-Font has participated as a sub-investigator in clinical trials sponsored by Mundipharma (Cambridge, UK) and Menarini Richerche (Florence, Italy). Dr. Camps-Font also reports grants and non-financial support from Avinent (Santpedor, Spain) outside the submitted work. Dr. Rui Figueiredo reports grants, personal fees, and non-financial support from Dentaid SL (Cerdanyola del Vall\u00e9s, Spain), MozoGrau (Valladolid, Spain), Avinent (Santpedor, Spain) and personal fees from BioHorizons Ib\u00e9rica (Madrid, Spain), Inibsa Dental (Lli\u00e7a de Vall, Spain), Dentsply implants Iberia (Barcelona, Spain), and ADIN Implants (Afula, Israel) outside the submitted work. Dr. Figueiredo has also participated as a principal investigator in a randomized clinical trial sponsored by Mundipharma (Cambridge, UK) and in another clinical trial as a sub-investigator for Menarini Richerche (Florence, Italy). Dr. Eduard Valmaseda-Castell\u00f3n reports personal fees and non-financial support from MozoGrau (Valladolid, Spain) and Avinent (Santpedor, Spain) and personal fees from BioHorizons Ib\u00e9rica (Madrid, Spain), Inibsa Dental (Lli\u00e7a de Vall, Spain), and Dentsply implants Iberia (Barcelona, Spain) outside the submitted work. Dr. Valmaseda-Castell\u00f3n has also participated as a sub-investigator in a randomized clinical trial sponsored by Mundipharma (Cambridge, UK). Bassel Traboulsi-Garet, Adri\u00e0 Jorba-Garc\u00eda, and Dr. Fabio Abreu Alves declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}